Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement

被引:0
作者
Bor-Sheng Ko
Cheng-Shyong Chang
Ming-Chih Chang
Tsai Yun Chen
Tzeon-Jye Chiou
Chang-Fang Chiu
Wen-Li Huang
Woei-Yau Kao
Yii-Jenq Lan
Shen-Fung Lin
Tran-Der Tan
Jih-Luh Tang
Cheng-Hwai Tzeng
Po-Nan Wang
Su-Pen Yet
Hwei-Fang Tien
机构
[1] National Taiwan University Hospital,Division of Hematology, Department of Internal Medicine
[2] National Health Research Institute,Institute of Systemic and Cellular Medicine
[3] Changhua Christian Hospital,Department of Internal Medicine
[4] Mackay Memorial Hospital,Department of Hematology
[5] Mackay Medical College,Oncology
[6] College of Medicine,Section of Hematology/Oncology, Department of Internal Medicine
[7] National Cheng Kung University,Division of Transfusion Medicine, Department of Medicine
[8] Taipei Veterans General Hospital,Cancer Center
[9] National Yang-Ming University School of Medicine,Department of Medicine
[10] China Medical University Hospital,Division of Hematology/Oncology
[11] School of Medicine,Division of Hematology
[12] China Medical University,Oncology, Department of Internal Medicine
[13] Taichung Veterans General Hospital,Division of Hematology
[14] Buddhist Tzu-Chi General Hospital Taipei Branch,Oncology, Department of Internal Medicine
[15] Chang Gung Memorial Hospital-Keelung,Division of Hematology
[16] Kaohsiung Medical University,Oncology, Department of Internal Medicine
[17] College of Medicine,Department of Internal Medicine
[18] Kaohsiung Medical University,Hematology and Medical Oncology
[19] Koo Foundation Sun Yat-Sen Cancer Center,Division of Hematology/Oncology, Department of Medicine
[20] Taipei Veterans General Hospital,Division of Hematology
[21] National Yang-Ming University School of Medicine,Oncology, Department of Internal Medicine
[22] Chang Gung Memorial Hospital-Linkou,undefined
来源
International Journal of Hematology | 2014年 / 100卷
关键词
Guidelines; Taiwan; MDS; ICT; Iron overload; Ferritin;
D O I
暂无
中图分类号
学科分类号
摘要
Iron overload is common in myelodysplastic syndrome (MDS) patients, and an accumulation of evidence shows that iron chelation may have benefits in these patients. However, discussion and consensus about iron chelation therapy (ICT) for MDS patients is lacking in Taiwan and other Southeast Asian countries. An Expert Panel in Taiwan was organized in 2011 to develop iron overload guidelines and provide a uniform reference for physicians treating MDS patients with iron overload, with specific regard to when to initiate ICT, in which patients, and the clinical and scientific rationale behind its use.
引用
收藏
页码:7 / 15
页数:8
相关论文
共 50 条
  • [31] Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Tsang, Erica
    Leitch, Heather A.
    [J]. ANNALS OF HEMATOLOGY, 2016, 95 (01) : 73 - 78
  • [32] Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Erica Tsang
    Heather A. Leitch
    [J]. Annals of Hematology, 2016, 95 : 73 - 78
  • [33] Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes
    Jabbour, Elias
    Kantarjian, Hagop M.
    Koller, Charles
    Taher, Ali
    [J]. CANCER, 2008, 112 (05) : 1089 - 1095
  • [34] Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
    Carreau, Nicole
    Tremblay, Douglas
    Savona, Michael
    Kremyanskaya, Marina
    Mascarenhas, John
    [J]. BLOOD REVIEWS, 2016, 30 (05) : 349 - 356
  • [35] The Role of Iron Chelation Therapy for Patients With Myelodysplastic Syndromes
    Steensma, David P.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (01): : 65 - 74
  • [36] Iron overload in myelodysplastic syndromes (MDS) -: diagnosis, management, and response criteria:: a proposal of the Austrian MDS platform
    Valent, P.
    Krieger, O.
    Stauder, R.
    Wimazal, F.
    Noesslinger, T.
    Sperr, W. R.
    Sill, H.
    Bettelheim, P.
    Pfeilstoecker, M.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 (03) : 143 - 149
  • [38] Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease
    Cerchione, Claudio
    Cerciello, Giuseppe
    Avilia, Simona
    Della Pepa, Roberta
    Pugliese, Novella
    Picardi, Marco
    Catalano, Lucio
    Pane, Fabrizio
    [J]. BLOOD TRANSFUSION, 2018, 16 (01) : 32 - 35
  • [39] Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes
    Hartmann, Julia
    Braulke, Friederike
    Sinzig, Ursula
    Wulf, Gerald
    Maas, Jens Holger
    Konietschke, Frank
    Haase, Detlef
    [J]. LEUKEMIA RESEARCH, 2013, 37 (03) : 327 - 332
  • [40] Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform
    Valent, Peter
    Stauder, Reinhard
    Theurl, Igor
    Geissler, Klaus
    Sliwa, Thamer
    Sperr, Wolfgang R.
    Bettelheim, Peter
    Sill, Heinz
    Pfeilstoecker, Michael
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (02) : 109 - 116